---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-005697"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:32:24.716530+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aethlon Medical Q1 net loss $2.6M; cash $9.1M; ethics approvals for Hemopurifier trial

## Summary
- Net loss $2.6M vs $3.3M YoY; operating expenses down 24% to $2.6M.
- Cash balance $9.1M as of June 30, 2024.
- Ethics approvals granted for Hemopurifier safety study in solid tumor patients on anti-PD-1 therapy.
- Expects to open patient enrollment in October 2024; additional sites anticipated by end of 2024.
- COVID-19 trial in India remains open; one patient treated to date.

## SEC filing metadata
- accession: 0001683168-24-005697
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316824005697/0001683168-24-005697-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316824005697/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-005697
- JSON: https://secwatch.observer/filing/0001683168-24-005697.json
- Plain text: https://secwatch.observer/filing/0001683168-24-005697.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.